Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without blocking D2 receptors.
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
CEO Daphne Zohar Total raised $100 million Headquarters Boston, MA On Thursday, members of Seaport Therapeutics’ founding ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback